Verona Pharma Share Discussion Threads

[vasilis] 23/9/2016 07:54

Thanks for that Tim.

Having read the article I notice that nothing is said about the excellent safety profile of RPL554. That would also be another strong 'Bull point' in my view.

Having said that, I'm glad that the article points out the significant impact that CF studies could have on RPL554's progress to market:-

'The World Health Organisation estimates that roughly three million people a year die of COPD and it is these severely ill patients for whom RPL554 is ideally targeted. Furthermore, with the potential to test in cystic fibrosis - a disease which currently has very limited treatment options - it could be fast-tracked through clinical studies, which may lead to an earlier-than-expected launch.'

[timbo003] 22/9/2016 18:28

There's a buy recommendation in tomorrow's Investors Chronicle, see abstract below, or for those who have access here's the link




Back Verona's blockbuster bet

UK pharmaceutical companies seem to have a particular affinity with the respiratory sector. Chronic obstructive pulmonary disorder (COPD) and asthma sufferers have been well catered for by AstraZeneca (AZN) and GlaxoSmithKline (GSK), whose drugs have dominated the market for many years. But this domination has led to a lack of innovation, particularly in the acute care and hospital setting, and therefore a lack of novel treatments......


IC VIEW:

For an early-stage biotech, Verona is very attractive. It is operating in an area of significant unmet need, with excellent trial data to date. Funding is in place for the next stage in its drug's development and while the limited focus makes this a very risky play, RPL554 comes with the tantalising prospect of blockbuster potential. Buy.

[thebossman] 20/9/2016 09:51

Hot off the press..


Home countries of the impacted athletes include Great Britain, Denmark, Canada, the USA and Spain.

Upon inspection, many of the drugs in the documents are steroid based anti-inflammatory medications or asthmatic treatments – including prednisolone, triamcinolone and salbutamol.

They could use RPL554 without side effects i guess..

[thebossman] 08/9/2016 12:32

Any poster got any info on how well or not the presention went in the states..thanks in advance..

Verona Pharma PLC Data on RPL554 to be presented at ERS Congress..5th 6th 7th sept 2016...

[vasilis] 30/8/2016 08:32

Tim

I look forward to reading your expert analysis of that patent application.

What seems very pleasing to me is that different acid based salt formations of RPL554 can be produced to have beneficial characteristics in both buffered solutions and dry crystalline formations. I presume that prepares us not just for future Phase III studies, but beyond bearing in mind what has been said by the company in respect of development for commercial DPI/MDI inhalers.

[bewise2] 30/8/2016 07:20

Rns....good stuff

[thebossman] 29/8/2016 11:31

Asthma Report: '1,000 Needless Deaths A Year.. This report could benefit vrp.

[timbo003] 25/8/2016 08:16

thanks (bewise and mol)

That looks like a very well drafted patent application regarding salt forms and it's going to take a while to read, digest and to put into context, so that's my weekend reading sorted....

[bewise2] 24/8/2016 22:36

Patent: inhalers.....interesting....mol :)

[kimangel] 24/8/2016 19:19

just a numbers game, surely no one has been fooled here.

[shearluc] 24/8/2016 19:15

Very Interesting, I thought VRP700 was dead and buried. However promising, the IIP market is small and i just hope they don't divert too much money from RPL554

[bewise2] 24/8/2016 18:53

Update on vrp 700....interesting development...thanks Mol

[ewads] 17/8/2016 18:40

Why the drop?

[shakin not stirred] 16/8/2016 17:29

presentation tomorrow? jak.

[bewise2] 11/8/2016 18:25

New hardman update out, very good and encouraging read :)

[bewise2] 09/8/2016 20:13

JAK presenting in New York next week:

Details on vrp website!

[bewise2] 09/8/2016 15:21

Shows confidence, very good indicator, I would imagine more to come as we progress, the large buys over the last week is also a good indicator of the rising sentiment in vrp .

[vasilis] 09/8/2016 14:21

Hurrah! -

Well done JAK. Walk the walk and all that.....

[bewise2] 05/8/2016 08:18

Unusual volumes yesterday....

[vasilis] 29/7/2016 12:03

Many thanks for that article Tim. Looks like GSK are paying quite a sum for an IL-33 inhibitor Phase I compound.

I'm not too au fait with these IL-33 studies but this site gives me a good overview -

I'm quite wary about anything which seems to have such potentially wide-ranging effects in such a manner since the chances for unwanted side effects can also increase in ways not envisaged. Note the warning at the end of the article :-

'However, many questions regarding the fundamental biology of IL-33 remain to be solved, including its nuclear effects and processing and release of IL-33 from cells. Furthermore, given the wide variety of cellular responses regulated by IL-33 and ST2, and in particular the cardio-protective effects of IL-33, this should be approached with caution.'

It will be interesting to see whether certain potentially beneficial effects observed in murine studies can be replicated in humans without potentially serious unwanted side effects.